What did the 2011 omega-3 trials show regarding ARDS?

Prepare for the ASPEN Certified Nutrition Support Clinician (CNSC) Exam. Study with structured quizzes and detailed insights to enhance your knowledge and readiness. Get set for success!

Multiple Choice

What did the 2011 omega-3 trials show regarding ARDS?

Explanation:
Omega-3 fatty acids were studied in ARDS because they were expected to modulate the inflammatory response and potentially improve lung injury. In 2011, randomized trials looked at an enteral formula enriched with omega-3s (EPA/DHA) plus gamma-linolenic acid and antioxidants. The findings showed no meaningful benefit on biomarkers of inflammation and no improvement in key clinical outcomes such as ventilator-free days, length of stay, or mortality. In other words, despite the theoretical rationale, the trials did not demonstrate a clinical or biological advantage. As a result, the evidence did not support routine use of omega-3–enriched nutrition for ARDS at that time.

Omega-3 fatty acids were studied in ARDS because they were expected to modulate the inflammatory response and potentially improve lung injury. In 2011, randomized trials looked at an enteral formula enriched with omega-3s (EPA/DHA) plus gamma-linolenic acid and antioxidants. The findings showed no meaningful benefit on biomarkers of inflammation and no improvement in key clinical outcomes such as ventilator-free days, length of stay, or mortality. In other words, despite the theoretical rationale, the trials did not demonstrate a clinical or biological advantage. As a result, the evidence did not support routine use of omega-3–enriched nutrition for ARDS at that time.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy